Get the Stockscreener App
7.38
8.69%
0.59
After Hours:
7.54
0.16
+2.17%
Kazia Therapeutics Limited Adr stock is traded at $7.38, with a volume of 372.43K.
It is up +8.69% in the last 24 hours and down -28.76% over the past month.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
See More
Previous Close:
$6.79
Open:
$6.8
24h Volume:
372.43K
Relative Volume:
1.61
Market Cap:
$114.75M
Revenue:
$26,600
Net Income/Loss:
$-14.73M
P/E Ratio:
-1.0819
EPS:
-6.8211
Net Cash Flow:
$-8.76M
1W Performance:
-16.33%
1M Performance:
-28.76%
6M Performance:
-26.20%
1Y Performance:
+2.22%
1-Day Range:
$6.80
$7.59
1-Week Range:
$6.62
$9.18
52-Week Range:
$4.86
$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Name
Kazia Therapeutics Limited Adr
Sector
Industry
Phone
01161298780088
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
7.38 | 114.75M | 26,600 | -14.73M | -8.76M | -6.8211 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Initiated | Canaccord Genuity | Buy |
| Jul-01-26 | Initiated | BTIG Research | Buy |
| Jun-11-26 | Initiated | Lake Street | Buy |
| Apr-15-26 | Initiated | Laidlaw | Buy |
| Feb-06-25 | Initiated | Maxim Group | Buy |
| Oct-14-21 | Initiated | Maxim Group | Buy |
| Jan-05-21 | Initiated | H.C. Wainwright | Buy |
View All
Kazia Therapeutics Limited Adr Stock (KZIA) Latest News
Zero voting power is reported as a holder amends its Kazia Therapeutics (KZIA) passive stake report. - Stock Titan
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq - The Globe and Mail
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) shifts ADSs to JPMorgan - Stock Titan
Kazia Therapeutics Limited Announces Change of Sole Depositary for Its American Depositary Receipt - marketscreener.com
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Paxalisib shrinks tumors in models as Kazia (NASDAQ: KZIA) lines up Phase 2 cancer trials - Stock Titan
BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com India
BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com UK
Kazia Therapeutics Expands Trial in HR+/HER2- Cancer | KZIA Stock News - Stock Titan
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - PR Newswire
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - The Manila Times
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) unveils new investor site - Stock Titan
Kazia Therapeutics (KZIA) structures up to $120M around cancer drug trials - Stock Titan
Kazia Therapeutics LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kazia Therapeutics stock falls on $40M public offering By Investing.com - Investing.com UK
Kazia Therapeutics prices $40 million public offering By Investing.com - Investing.com UK
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering - The Globe and Mail
Kazia Therapeutics Limited Announces Proposed Public Offering - The Manila Times
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering - PR Newswire
Kazia Therapeutics (KZIA) trims at-the-market offering program to $80M - Stock Titan
Kazia Therapeutics LimitedADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Kazia Therapeutics Limited Announces Proposed Public Offering - BioSpace
Kazia Therapeutics launches public offering of ADSs and warrants - Investing.com
Kazia Therapeutics Limited Announces Proposed Public Offering - The Globe and Mail
Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake - Stock Titan
Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap - Stock Titan
Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS - Stock Titan
KZIA Q2 2026 Earnings: Wider-Than-Expected Loss Magnifies Cash Burn Concerns for Clinical-Stage Biotech - dars.gov.et
KZIA Q2 2026 Earnings: Wider-Than-Expected Loss Magnifies Cash Burn Concerns for Clinical-Stage BiotechAnalyst Coverage Count - dars.gov.et
KZIA Q2 2026 Earnings: Wider-Than-Expected Loss Magnifies Cash Burn Concerns for Clinical-Stage BiotechDividend Growth Analysis - https://www.dars.gov.et/
Kazia Therapeutics (KZIA) Holds Near $13.95 as Biotech ADR Consolidates Between Key LevelsParabolic SAR - vinanet.vn
Kazia files patent for breast cancer treatment strategy By Investing.com - Investing.com Nigeria
Kazia Therapeutics (NASDAQ: KZIA) files patent backed by TNBC data - Stock Titan
KZIA|Kazia Therapeutics Ltd|Price:12.802|Chg%:+0.542 - TradingKey
Kazia Therapeutics (KZIA) Slides 6% as Biotech Volatility Tests Key Support LevelCounter Trend Trade - dars.gov.et
Kazia (KZIA) Jumps +2.36% — Is Institutional Money Flowing In? 2026-07-17Gamma Squeeze - dars.gov.et
Kazia Therapeutics (KZIA) grants director 100,000 stock options - Stock Titan
KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant - Stock Titan
Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance - Stock Titan
Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options - Stock Titan
Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director - Stock Titan
Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78 - Stock Titan
BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria
BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Canada
BTIG initiates Kazia Therapeutics stock with buy on cancer drug - Investing.com
Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView
Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan
Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):